Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.46 |
| ▸ | PPARD | Q03181 | 8/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 5/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2874509 | 0.90 | IDH1 (0.50) | PPARAPPARDFFAR1FFAR4PPARG | |
| SCHEMBL13513783 | 0.79 | PPARD (0.61) | PPARAPPARDFFAR1PPARG | |
| SCHEMBL29459594 | 0.78 | PPARD (0.58) | PPARAPPARDFFAR1PPARG | |
| SCHEMBL2869616 | 0.78 | PPARD (0.58) | PPARAPPARDFFAR1PPARG | |
| SCHEMBL13513792 | 0.76 | PPARD (0.75) | PPARAPPARDPPARG | |
| SCHEMBL2874504 | 0.74 | PPARD (0.50) | PPARAPPARDFFAR1PPARGIDH1 | |
| SCHEMBL10946026 | 0.73 | CYP1A2 (0.51) | PPARAPPARDTDP1PPARGIDH1 | |
| SCHEMBL13512225 | 0.72 | PPARD (0.63) | PPARAPPARDPPARG | |
| SCHEMBL13513779 | 0.72 | PPARD (0.56) | PPARAPPARDFFAR1PPARG | |
| SCHEMBL25212758 | 0.71 | CYP1A2 (0.59) | PPARAPPARDTDP1PTGDR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435946-B1 | LINKED BIARYL COMPOUNDS | AMGEN INC (US) | 2013-11-06 | — | — | EP | disclosed |
| US-7645779-B2 | Linked biaryl compounds | AMGEN INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080161351-A1 | Linked biaryl compounds | TULARIK INC. | 2008-07-03 | — | — | US | disclosed |
| EP-1435946-A4 | LINKED BIARYL COMPOUNDS | TULARIK INC (US) | 2006-02-01 | — | — | EP | disclosed |
| US-6869975-B2 | Linked biaryl compounds | TULARIK INC. (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1435946-A2 | LINKED BIARYL COMPOUNDS | Tularik Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030149108-A1 | Linked biaryl compounds | TULARIK INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003024395-A2 | LINKED BIARYL COMPOUNDS | TULARIK INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149108-A1 | Linked biaryl compounds | SREBF2, SREBF1, ACACB | PPARA 89/4885PPARD 55/4885FFAR1 433/4885 |
| US-20080161351-A1 | Linked biaryl compounds | SREBF2, SREBF1, ACACB | PPARA 89/4885PPARD 55/4885FFAR1 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.